Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on . “
data-action=”subscribe”>
Subscribe
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Key takeaways: Independent predictors of COMPASS-31 included EoE disease activity and hypermobility. The correlation between COMPASS-31 and a quality of life survey was negative. Among pediatric patients with eosinophilic esophagitis, around a quarter had joint hypermobility, according to results published in The Journal of Allergy and Clinical Immunology. Researchers went on to find that this group of patients had a significantly higher score on a questionnaire measuring autonomic symptoms vs. those without hypermobility, signaling greater symptom severity.
\u201cOur study highlights a vital need for clinicians to screen for autonomic symptoms and hypermobility,\u201d Joshua B. Wechsler, MD, MSCI, medical director of the eosinophilic gastrointestinal diseases program at Lurie Children\u2019s Hospital of Chicago, told Healio. \u201cBoth of these ultimately have straightforward treatment options that are effective for many patients. \u201cFor postural lightheadedness, many patients respond to increased fluids, salt, cardio and lower leg muscle strengthening,\u201d Wechsler, who also is assistant professor of pediatrics and medicine at Northwestern University Feinberg School of Medicine, said. \u201cFor hypermobile patients, physical therapy and stable physical activity are crucial.\u201d In a prospective study, Wechsler and colleagues assessed 80 patients aged 2 to 21 years (mean age, 11 years; 21% female; 92% white) with EoE undergoing esophagogastroduodenoscopy to determine how autonomic symptoms are linked to symptoms, quality of life and mast cells (gastric and duodenal). Researchers also evaluated how joint hypermobility is linked to the same outcomes. According to Wechsler, five factors prompted this study. \u201cPublished literature supports increased connective tissue disorders in EoE, yet no study focused on hypermobility in particular,\u201d he said. \u201c[There is also a] close association between [postural orthostatic tachycardia syndrome (POTS)] and hypermobility.\u201d Wechsler told Healio the third factor was an anecdotal observation. \u201cPostural lightheadedness was common when I would meet patients, and often I was the first doctor identifying POTS,\u201d he said. The last two factors were an \u201cappreciation that POTS may be a cause of GI symptoms and poor quality of life\u201d and \u201crecognition that EoE patients often have \u2018unexplained symptoms\u2019 that can\u2019t be directly attributed to the EoE itself,\u201d according to Wechsler. Data collection Researchers obtained data on autonomic symptoms from patients\/caregivers using the Composite Autonomic Symptom Score 31 (COMPASS-31). For joint hypermobility, a five-question survey from the 2017 international classification of Ehlers-Danlos syndrome and the Beighton score were used. Additional surveys were completed to measure the studied outcomes: the Pediatric Quality of Life Inventory (PedsQL) for quality of life; the Pediatric Eosinophilic Esophagitis Symptom Score (PEESS) and PedsQL EoE module for EoE symptoms; and the Dyspepsia Symptom Survey for gastric\/duodenal symptoms. For mast cells, the study also collected gastric and duodenal biopsy samples. Results COMPASS-31 was significantly greater in the EoE population vs. a published control cohort of asymptomatic pediatric patients (P < .001). When the EoE cohort was broken down by disease activity (active EoE, n = 45; remission, n = 35), researchers found a significantly greater COMPASS-31 among those with active EoE vs. in remission (P = .02). The correlation between COMPASS-31 and PEESS Parent and Child composite scores was positive, as was the correlation between COMPASS-31 and three of four PEESS domain scores: gastroesophageal reflux, nausea\/vomiting and pain. In contrast, the correlation between COMPASS-31 and PedsQL scores from parents and children was negative, according to the study. Switching to hypermobility, the EoE population consisted of 26% with hypermobility and 74% without hypermobility. In the set of patients with EoE, researchers observed a significantly greater COMPASS-31 among those with vs. without hypermobility (P = .003). \u201cI was surprised at how common hypermobility and postural lightheadedness was among the patients,\u201d Wechsler told Healio. \u201cAs both of these conditions can impact quality of life, identification is a key first step,\u201d he added. \u201cKnowing that the EoE population is a vulnerable population emphasizes the need for screening.\u201d The study further highlighted that independent predictors of COMPASS-31 included disease activity (P < .01) and hypermobility (P < .01) in linear regression. In the analysis of COMPASS-31 and the density of gastric and duodenal mast cells, no significant link emerged between the two factors. This outcome was also found between hypermobility and mast cell density. \u201cI was surprised that we didn\u2019t see associations with mast cells, but the relationship may be much more complex than simple enumeration of mast cell density,\u201d Wechsler told Healio. \u201cWe don\u2019t currently understand if the pathogenesis of hypermobility and dysautonomia ultimately intersect or fuel EoE itself, so future studies should evaluate this more closely,\u201d Wechsler said. \u201cIn addition, we don\u2019t know if longitudinal outcomes are different in this subtype.\u201d For more information: Joshua B. Wechsler, MD, MSCI, can be reached at j-wechsler@northwestern.edu. Sources\/Disclosures Source: Patel RH, et al. J Allergy Clin Immunol. 2026;doi:10.1016\/j.jaci.2026.05.027. Reference:
Disclosures:
Wechsler reports being a consultant and\/or speaker for AstraZeneca, Bristol Myers Squibb, Celldex, Ellodi, Sanofi-Regeneron and Takeda; and receiving clinical trial\/research funding from Sanofi-Regeneron. All other study authors report no relevant financial disclosures.
Ask a clinical question and tap into Healio AI’s knowledge base.
PubMed, enrolling\/recruiting trials, guidelines
Clinical Guidance, Healio CME, FDA news
Healio’s exclusive daily news coverage of clinical data
Learn more
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on . “
data-action=”subscribe”>
Subscribe
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Source link<\/p>\n","protected":false},"author":1,"featured_media":3101,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-3100","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/posts\/3100","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3100"}],"version-history":[{"count":0,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/posts\/3100\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/media\/3101"}],"wp:attachment":[{"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3100"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3100"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3100"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}